PTC Therapeutics, Inc., headquartered in South Plainfield, announced the promotion of Emily Hill to chief financial officer. Hill joined PTC Therapeutics in November 2013 and was most recently senior vice president and head of investor relations.
“It is my pleasure to announce Emily’s promotion to CFO,” said Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. “Emily has a deep knowledge of our industry and has strong relationships and understanding of the investor community. Emily has a great track record of leadership at PTC and will be part of the executive team to deliver value to patients and shareholders as we continue to realize our vision of bringing more treatments to patients living with rare disorders.”
Prior to joining PTC Therapeutics, Hill was director of investor relations of Warner Chilcott where she was responsible for leading the function. Additionally, Hill was senior manager of investor relations at Genzyme Corporation. Prior to Genzyme, Hill was a biotech equity research associate at Summer Street Partners. Hill has an MBA with a concentration in Finance from Fordham University, a Masters of Science in Pharmacology from Tufts University School of Biomedical Research, and a BA from Hamilton College.
To access more business news, visit NJB News Now.Related Articles: